<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02651285</url>
  </required_header>
  <id_info>
    <org_study_id>CRH2016/01</org_study_id>
    <nct_id>NCT02651285</nct_id>
  </id_info>
  <brief_title>Use of G-CSF Supplemented IVF Medium in Patients Undergoing IVF</brief_title>
  <official_title>G-CSF Supplemented Medium for IVF Embryo Culture in Patients Undergoing IVF</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre for Endocrinology and Reproductive Medicine, Italy</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre for Endocrinology and Reproductive Medicine, Italy</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether in Assisted Reproductive Technologies the
      use of culture medium supplemented with G-CSF, a growth factor working on stem cells, may
      improve the embryo implantation and pregnancy rate in infertile patients undergoing IVF
      cycles.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In Assisted Reproductive Technologies the rate of pregnancy for cycle and the implantation
      rate remain low nevertheless the improvement in the last years. In particular also in
      relatively young reproductive age women nevertheless the good embryos produced and
      transferred pregnancy rate and implantation rate remain low. Recently, it has been showed
      that culture medium supplemented with G-CSF, may improve the embryo outcomes in IVF. In this
      trial the investigators will test the potential benefits of this culture medium on embryos of
      patients undergoing IVF. 180 infertile women undergoing IVF no more than 37 years old will be
      selected. These patients will be assigned to two arms, one experimental and one other of
      control by a computer generated sequence. After the oocyte retrieval and fertilization by
      ICSI procedure, the fertilised oocyte (2PN)will cultured with the G-CSF supplemented culture
      medium or in normal culture in micro drop of 30microliters under oil until the day of
      transfer (day five or blastocyst sage embryos). A maximum of two embryos will be transferred.
      The pregnancy rate, implantation rate and number of blastocyst developped will be the
      outcomes considered
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>January 2016</start_date>
  <completion_date type="Anticipated">March 2017</completion_date>
  <primary_completion_date type="Anticipated">December 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>pregnancy rate</measure>
    <time_frame>12 months</time_frame>
    <description>The number of patients become pregnant after IVF where G-CSF medium is used divided for the number of patients treated</description>
  </primary_outcome>
  <primary_outcome>
    <measure>implantation rate</measure>
    <time_frame>12 months</time_frame>
    <description>The number of embryos implanted after IVF where G-CSF medium is used divided for the number of embryos transferred</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>number of blastocyst developped</measure>
    <time_frame>12 months</time_frame>
    <description>The number of blastocysts obtained after IVF where G-CSF medium is used divided for the number of fertilized oocytes</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">180</enrollment>
  <condition>Infertility</condition>
  <condition>Embryo Development</condition>
  <condition>IVF</condition>
  <arm_group>
    <arm_group_label>G-CSF</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The embryos obtained with IVF in patients included iin this arm will be incubated after fertilization with medium supplemented with G-CSF</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CONTROL</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>The embryos obtained by women undergoing IVF included in this arm will be incubated with a standard medium for IVF, and utilized as control group.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>G-CSF medium</intervention_name>
    <description>incubation of IVF embryos with a specific medium containing G-CSF</description>
    <arm_group_label>G-CSF</arm_group_label>
    <other_name>(granulokine)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Control</intervention_name>
    <description>incubation of IVF embryos with a medium without G-CSF</description>
    <arm_group_label>CONTROL</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  infertility

          -  healthy condition,

          -  good ovarian reserve (AMH levels more than 1microg/ml)

        Exclusion Criteria:

          -  chromosomal defects in the couple,

          -  metabolic diseases (diabetes, etc),

          -  other genetic diseases (thalassemia, cystic fibrosis, etc.)
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>38 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Francesco Morgia, MS</last_name>
    <role>Study Chair</role>
    <affiliation>Centre for Endocrinology and Reproductive Medicine, Italy</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Marco Sbracia, MD</last_name>
    <phone>+393479037433</phone>
    <email>marcandrea@hotmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Fabio Scarpellini, MD</last_name>
    <phone>+393278779064</phone>
    <email>quelidebercia@hotmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Cerm-Hungaria</name>
      <address>
        <city>Rome</city>
        <zip>00153</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>MARCO SBRACIA, MD</last_name>
      <phone>+393479037433</phone>
      <email>marcandrea@hotmail.com</email>
    </contact>
    <contact_backup>
      <last_name>FABIO SCARPELLINI, MD</last_name>
      <phone>+393278779064</phone>
      <email>quelidebercia@hotmail.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>January 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 7, 2016</study_first_submitted>
  <study_first_submitted_qc>January 7, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 8, 2016</study_first_posted>
  <last_update_submitted>January 7, 2016</last_update_submitted>
  <last_update_submitted_qc>January 7, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 8, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Centre for Endocrinology and Reproductive Medicine, Italy</investigator_affiliation>
    <investigator_full_name>Fabio Scarpellini</investigator_full_name>
    <investigator_title>Clinical Director</investigator_title>
  </responsible_party>
  <keyword>G-CSF</keyword>
  <keyword>BLASTOCYST</keyword>
  <keyword>IVF</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infertility</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lenograstim</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

